Sangamo Therapeutics, Inc. reported impairment charges for the first quarter ended March 31, 2024. For the quarter, the company reported impairment of long-lived assets of $4,349,000 compared to $20,433,000 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.595 USD | -3.71% | -8.44% | +9.48% |
May. 09 | Transcript : Sangamo Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
May. 09 | Earnings Flash (SGMO) SANGAMO THERAPEUTICS Reports Q1 Revenue $481,000 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.48% | 128M | |
+12.02% | 116B | |
+12.98% | 106B | |
-9.23% | 23.89B | |
-1.69% | 21.58B | |
-10.60% | 18.96B | |
-41.25% | 16.96B | |
-14.55% | 16.33B | |
+6.55% | 14.14B | |
+30.68% | 12.02B |
- Stock Market
- Equities
- SGMO Stock
- News Sangamo Therapeutics, Inc.
- Sangamo Therapeutics, Inc. Reports Impairment Charges for the First Quarter Ended March 31, 2024